Congress Materials

Medical Information
Gulf Countries
 

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
SelectI am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
I am a patient / caregiverNo, go back to the patient portal
SelectI am a patient / caregiverNo, go back to the patient portal
I am a Healthcare Professional in another country.
The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Oral Presentation
Erman Guler, Peter Anderson, Simran Marwaha, James Piercy, David Gruben, Andrey Lvov, Magdalena Trzeciak, Magdalena Czarnecka-Operacz March 29, 2022 AAD 2022 Atopic Dermatitis

Atopic Dermatitis Treatment Patterns and Patient Burden in Russia and Poland

View Presentation
Oral Presentation
Raj Chovatiya, Maria Concetta Fargnoli, Brett King, Vivian Shi, Christian Vestergaard, Luis Puig, Pinaki Biswas, Marco DiBonaventura, Mark Levenberg, Claire Clibborn March 29, 2022 AAD 2022 Atopic Dermatitis

Characteristics of the Efficacy Response Trajectory Among Patients Who Did Not Flare During the Maintenance Phase of JADE REGIMEN

View Presentation
Oral Presentation
Andrew F. Alexis, Zakiya P. Rice, Kenji Kabashima, Paula C. Luna, Jacob P. Thyssen, Magdalena Trzeciak, Pinaki Biswas, Gary L. Chan, Erman Guler, Mark Levenberg March 29, 2022 AAD 2022 Atopic Dermatitis

Efficacy and Safety of Abrocitinib According to Geographies

View Presentation
Oral Presentation
Hordinsky M, Hebert A, Gooderham M, Kwon O, Murashkin N, Tran H, Wajsbrot D, Takiya L, Zwillich SH, Wolk R March 29, 2022 AAD 2022 Alopecia Areata

Efficacy and safety of the oral JAK3/TEC inhibitor ritlecitinib in adolescents with alopecia areata: results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial

View Presentation
Oral Presentation
Mesinkovska N, Shapiro J, King B, Sinclair R, Zhang X, Lynde C, Gubelin Harcha W, Szepietowski JC, Wajsbrot D, Takiya L, Wolk R March 29, 2022 AAD 2022 Alopecia Areata

Efficacy of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata over 48 weeks: results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial

View Presentation
Oral Presentation
Sinclair R, Mesinkovska N, Mitra D, Wajsbrot D, Wolk R, King B March 29, 2022 AAD 2022 Alopecia Areata

Improvement in patient reported hair loss outcome measures in patients with alopecia areata treated with ritlecitinib: 48-week results from the ALLEGRO Phase 2b/3 randomized, double-blind, placebo-controlled trial

View Presentation
Oral Presentation
Amy Paller, Lawrence F. Eichenfield, Michael J Cork, Christine Bangert, Alan D. Irvine, Stephan Weidinger, Susan Johnson, Irina Lazariciu, Herwig Koppensteiner March 29, 2022 AAD 2022 Atopic Dermatitis

Integrated Analysis of Abrocitinib for the Treatment of Adolescents with Moderate-to-Severe Atopic Dermatitis From the Phase 3 Clinical Trial Program

View Presentation
Oral Presentation
Gandhi K, Fridman M, Ray M, Shy M, Mostaghimi A, Bartolome L March 29, 2022 AAD 2022 Alopecia Areata

Looking Beyond Scalp Hair Loss: Factors Influencing Dermatologists’ Assessment of Alopecia Areata Severity

View Presentation
Oral Presentation
Joy Wan, Daniel B Shin, Maha N Syed, Katrina Abuabara, Adina R Lemeshow, Joel M Gelfand March 29, 2022 AAD 2022 Atopic Dermatitis

Malignancy risk among children and adults with atopic dermatitis in a population-based cohort

View Presentation
Oral Presentation
Peeva E, Yamaguchi Y, King B, Han G, Cox L, Banerjee A, Picardo M, Bae JM, Sloan A, Sinclair R, Ezzedine K March 29, 2022 AAD 2022 Vitiligo

Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, shows efficacy in patients with active non-segmental vitiligo across Fitzpatrick skin types: results from a Phase 2b, randomized, dose-ranging study with an extension period

View Presentation